Amylin news

All news on Amylin (also known as Islet amyloid polypeptide and IAPP): plants, production capacities, investments and involved companies.

7 June 2026

Novo Nordisk CagriSema Phase 3 trials show large HbA1c and weight reductions

Once‑weekly cagrilintide+semaglutide reduced HbA1c by up to 2.33 percentage points and bodyweight by up to 14.2% across REIMAGINE 1–3 versus comparators.
5 June 2026

Novo Nordisk zenagamtide (amycretin) delivers large HbA1c and weight reductions in phase 2 T2D trial

Unimolecular GLP‑1/amylin agonist produced substantial HbA1c and weight reductions in a 36‑week phase 2 trial in adults with type 2 diabetes on metformin ± SGLT2i.
5 March 2026

Roche Reports Positive Phase II Results for Petrelintide in Obesity Treatment

Petrelintide shows significant weight loss and good tolerability in Phase II trial, supporting further development for chronic weight management.
5 March 2026

Genentech Reports Positive Phase II Results for Petrelintide in Obesity Treatment

Petrelintide shows significant weight loss and good tolerability in Phase II trial, supporting further development for chronic weight management.
16 September 2025

Novo Nordisk Advances Cagrilintide to Phase 3 Clinical Program After Positive Results

Cagrilintide shows significant weight loss and tolerability in trials, prompting further study in the RENEW phase 3 program for obesity treatment.

Who will be producing Amylin in the future?

Find out with chemXplore Alpha

Learn more